Targeting DNMT1 by Demethylating Agent OR-2100 Increases Tyrosine Kinase Inhibitors-Sensitivity and Depletes Leukemic Stem Cells in Chronic Myeloid Leukemia

OR21 exhibited anti-tumor effects as a monotherapy, and in combination therapy it increased tyrosine kinase inhibitors -induced apoptosis and induction of tumor suppressor genes including PTPN6 encoding SHP-1 in chronic myeloid leukemia cells.